This paper is a practical guide to the essentials of statistical analysis and reporting of randomized clinical trials (RCTs). It is the first in a series of 4 educational papers on statistical issues for RCTs, which will also include statistical controversies in RCT reporting and interpretation, the fundamentals of design for RCTs, and statistical challenges in the design and monitoring of RCTs. Here, we concentrate on displaying results in tables and figures, estimating treatment effects, expressing uncertainty using confidence intervals, and using p values wisely to assess the strength of evidence for a treatment difference. The various methods and their interpretation are illustrated by recent, topical cardiology trial results. (J Am Coll Cardiol 2015;66:2536-49)
After these first 2 papers on statistical analysis and reporting of clinical trials, 2 subsequent papers will focus on statistical design of randomized trials and also data monitoring. The principles are brought to life by real topical examples, and besides laying out the fundamentals, we also tackle some common misperceptions and some ongoing controversies that affect the quality of research and its valid interpretation.
Constructive critical appraisal is an art continually exercised by journal editors, reviewers, and readers, and is also an integral part of good statistical science that we hope to encourage via our choice of examples.
Throughout this series, we concentrate on concepts rather than providing formulae or calculation techniques, therefore ensuring that readers without a mathematical or technical background can grasp the essential messages we wish to convey.
THE ESSENTIALS OF STATISTICAL ANALYSIS
The 4 main steps in data analysis are:
Displaying results in tables and figures
2. Quantifying any associations (e.g., estimates of treatment differences in patient outcomes) 3 . Expressing the uncertainty in those associations by use of confidence intervals (CIs) 4 . Assessing the strength of evidence that the association is "real" (i.e., more than could be expected by chance) by using p values (statistical tests of significance)
The next few sections take us through these essentials, illustrated by examples from randomized trials. The same principles broadly apply to observational studies, with 1 major proviso: in nonrandomized studies, one cannot readily infer that any association not due to chance indicates a causal relationship.
Also, next week we discuss some of the more challenging issues when reporting clinical trials. teristics by treatment group. Which characteristics to present will vary by trial, but will almost always include key demographic variables, related medical history, and other variables that might be strongly related to the trial endpoints. See Table 1 For variables with a skew distribution, the latter is often preferable, geometric means being another option. In addition, some such variables may be formed into categories, for example, age groups or specific (abnormal) cut-offs for biochemical variables. This (and indeed any other table) should include the total number of patients per group at the top. To limit the size of Table 1 , a third column showing results for all groups combined may be unnecessary. Also, for some binary variables (e.g., sex or disease history) only 1 category (e.g., male or diabetic) need be shown. Unnecessary precision in reporting means or percentages should be avoided, with 1 decimal place usually being sufficient. The use of p values in baseline tables should also be avoided, because in the setting of a well-conducted RCT, any differences at baseline must have arisen by chance. For any composite event (e.g., death, myocardial infarction, and stroke), the number of patients experiencing any of them (i.e., the composite) plus the numbers in each component should all be shown. Because some patients can have more than 1 type of event (e.g., nonfatal myocardial infarction followed by death), the numbers in each component usually add up to slightly more than the numbers with composite events.
DISPLAYING RESULTS IN TABLES AND FIGURES
The focus is often on time to first event, so any subsequent (repeat) events (e.g., a second or third myocardial infarction) do not get included in the main analyses. This is not a problem when the frequency of repeat events is low. But for certain chronic disease outcomes, such as hospitalization for heart failure, repeat events are more common. For instance, in the CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) trial (3) of rosuvastatin versus placebo in chronic heart failure, there were a total of 2,408 heart failure hospitalizations in 1,291 of 5,011 randomized patients. Conventional analyses of time to first hospitalization was inconclusive, but analyses using all hospitalizations (including repeats) gave strong evidence of a treatment benefit in that secondary outcome (4).
In trials of chronic diseases (e.g., chronic heart failure), in which the incidence rates over time are fairly steady, it may be useful to replace % by the incidence rate per 100 patient-years, for example, of follow-up in each group: to calculate the incidence rate one divides the number of patients with the relevant event by the total follow-up time in years of all patients (excluding any follow-up after an event occurs). Such a table will usually add in estimates of treatment effect, CIs, and p values, as dealt with in the next 3 sections, and already shown in Table 2 .
Another important table concerns adverse events by treatment group. Kaplan-Meier plot (6) . The numbers at risk in each group should be shown at regular time intervals of follow-up. In this case, we see that nearly all patients had 6 months of follow-up, but only around one-half of patients were followed for 1 year. In connection with this, we recommend that the time axis should not be extended too far, perhaps not beyond the time when <10% of patients are still under follow-up. 
Making Sense of Statistics: Part 1 One good practice that is, sadly, rarely done is to convey the extent of statistical uncertainty in the estimates over time by plotting standard error (SE) bars at regular time points. In this case, the SEs would be much tighter at 6 months compared with 1 year, reflecting the substantial proportion of patients not followed out to 1 year.
Sometimes, Kaplan-Meier plots are inverted, thereby showing the declining percentage of patients over time that are event free. This can be particularly misleading if there is a break in the vertical axis (which readers may not spot). In general, we feel it is more informative to have the curves going up (not down), thereby focusing on cumulative incidence, with a sensible range (up to 12% in this case) rather than a full vertical axis up to 100%, so that relevant details, especially regarding treatment differences, can be clearly seen. The choice of vertical scale is an important ingredient in interpreting these plots; not so wide (0% to 100%) as to cramp the visual effect, but not so tight as to exaggerate any small differences that may occur. Values are mean AE SD, n (%), or median (interquartile range). steps along the way documented, each with patient numbers. Note that with a more conventional patient consent prior to randomization, the trial profile would become somewhat simplified.
The next most common figure is the forest plot for subgroup analyses, but more on that in next week's paper.
ESTIMATES OF TREATMENT EFFECTS AND THEIR CIs
Now we get down to the serious business of estimating the magnitude of the difference between treatments on patient outcomes. First, we wish to obtain a point estimate, that is, the actual difference observed. Then we need to express the degree of uncertainty present in the data, that is, the bigger the trial, the more precise the point estimate will be. Such uncertainty is usually expressed as a 95% CI.
Exactly what type of estimate is required depends on the nature of the patient outcome of interest.
There are 3 main types of outcome data: EXPRESSING UNCERTAINTY USING CIs. All estimates based on percentages, such as in Table 3 (and, indeed, other types of estimates to follow in the next 2 sections) are not to be trusted at face value. Any estimate has a built-in imprecision because of the finite sample of patients studied, and indeed the smaller the study, the less precise the estimate will be. The extent of such statistical uncertainty is best captured by use of a 95% CI around any estimate (10, 11 Pocock et al. 
Making Sense of Statistics: Part 1 precise meaning as follows. If we were to repeat the whole clinical trial many, many times using an identical protocol we would get a slightly different confidence interval each time. Of those CIs, 95% would contain the true underlying relative risk reduction.
But, whenever we calculate a 95% CI, there is a 2.5%
chance that the true effect lies below and a 2.5%
chance that the true effect lies above the interval.
What matters here is that the whole 95% CI indicates a clear relative risk reduction. This is reinforced by 95% CI for the difference that is from À0.35% to À2.03% (Table 3) . These relatively tight CIs, each wholly in a direction substantially favoring cangrelor, provides strong evidence that cangrelor reduces the risk of the primary endpoint compared with clopidogrel. Later, we achieve the same message by use of a p value. Note that Table 3 also gives a 95% CI for the NNT. Some trials report the NNT but not its 95% CI, a practice to be avoided because readers can be led astray by thinking that the NNT is precisely known.
An important obvious principle is that larger studies (more patients and hence more events) produce more precise estimation and tighter CIs. Specifically, to halve the width of a CI, one needs 4Â as many patients. ESTIMATES FOR TIME-TO-EVENT OUTCOMES. Many major clinical trials have a primary outcome, which is time to an event. In the PLATO trial (5) (Figure 1) , the Kaplan-Meier plot is for time to the primary composite outcome of death, myocardial infarction, and stroke. composite endpoint of death, myocardial infarction, or stroke (Figure 4 ). An early excess event rate for CABG (mainly due to stroke) is followed by a lower event rate after the first 6 months. The Kaplan-Meier curves cross at around 1 year. Here, a hazard ratio would be a peculiar average of early bad news followed by later good news for CABG, and so is not particularly useful. The focus on the 5-year composite event rate (18.7% on CABG, 26.6% on PCI) is informative, but suffers from the fact that only around one-third of patients have so far been followed for 5 years. A more complete 5-year followup is required to clarify this.
Another problem with hazard ratios is that they focus on a "vertical interpretation" of the KaplanMeier plot. But, in chronic diseases, a more "horizontal interpretation" focusing on event-free time gained may be more appropriate. The accelerated failure time model (14) is unfortunately rarely used, but it can nicely capture this concept. In a nutshell, it estimates a time ratio whereby if a new treatment helps to delay the occurrence of events, the time ratio will be >1. Making Sense of Statistics: Part 1 treatment effect, that is, its 95% CI is a bit tighter (18) . Even so, in this case, the 95% CI still includes zero treatment difference, meaning that there is insufficient evidence that renal denervation lowers SBP in this population.
What ANCOVA is doing is illustrated in Figure 6 , Pocock et al.
follow-up, to provide the most valid estimate based on the totality of patient data.
Sometimes, a quantitative outcome has a highly skewed distribution so that a conventional analysis of means becomes unstable because of its dependence on a few extreme values. Options then are: 1) to use a suitable transformation (e.g., natural logarithm leading to comparison of geometric means);
2) to use nonparametric analyses, often focusing on a comparison of medians; or 3) to focus on a particular cut-off value(s) (e.g., the upper limit of normal in liver function tests) with a consequent comparison of percentages.
p VALUES AND THEIR INTERPRETATION
We have deliberately delayed explaining p values until after covering descriptive statistics, estimation, and CIs. This is an attempt to counter the obsessive tendency for people to classify a clinical trial into "positive" or "negative" depending on whether or not the primary endpoint achieves p < 0.05. This oversimplification is an abuse of the p value, which can be a valuable statistical tool when interpreted appropriately.
Alongside an estimate of treatment difference and its 95% CI, the corresponding p value is the most succinct direct route to expressing the extent to which it looks plausibly like a real treatment effect, or rather could readily have arisen by chance. At the heart of any significance test is the null hypothesis that the 2 treatments are identical in their effect on the outcome of interest. The p value is the probability of obtaining a treatment difference at least as great (in either direction) as that actually observed if the null hypothesis were true. The smaller the p value, the stronger the evidence against the null hypothesis, that is, the more convincing the evidence is that a genuine treatment difference exists.
Let us consider some recent trials to elucidate the range of their p values for the primary endpoint. In doing so, our aim is to translate statistical evidence into plain English (19) . The PARADIGM-HF trial (1) compared a new drug, LCZ696, with enalapril in patients with chronic heart failure. For the primary we still cannot assert definitively that aliskiren has no effect: the hazard ratio is in the direction of slightly fewer primary events on aliskiren and the wide CI extends a substantial distance from neutrality (hazard ratio: 1) in both directions.
Thus, we may think of p values not as a "black and white" significant/nonsignificant dichotomy, but more in terms of "shades of gray" (22) . This analogy to a recent movie is not to make statistics sexy, nor is it to suggest that statisticians are sadists, but it is more in the spirit of the expression's original meaning. The smaller the value of p, the stronger the evidence to contradict the null hypothesis of no true treatment difference. We can think of p < 0.000001 as "pure white" and p ¼ 0.99 as "pure black," with a trend of increasingly darkening grayness in-between those extremes. (23) is to remind us all that interpretation of a seemingly "positive" trial rests on more than just a significant p value:
1. It is good practice to give the actual p value (i.e., p ¼ 0.042 rather than p < 0.05 or crudely "significant," or p ¼ 0.061 rather than "not significant").
2. It is useful to recognize the link between the p value and the 95% CI for the treatment difference. If the latter includes no difference, that is, 0 on an absolute scale (e.g., % or mean difference) or 1 on a There may be biases in the study design and conduct (e.g., randomization could be absent or flawed, lack of appropriate blinding, or incomplete followup), which contribute wholly or in part to the apparent treatment difference. These issues contribute to why regulators often require 2 trials be conducted to demonstrate a reassuring consistency of findings in 2 different settings. Table 6 ). See Table 7 for how it works for 4 of the trials we have already Tables 1 and 3. discussed. In each case, this simple test agrees well with the more complex calculations used in the trial publication.
CONCLUSIONS
We have covered the essentials of statistical analysis and reporting in this paper, and the key aspects are summarized in the Central Illustration. Next week we tackle a variety of more complex statistical challenges that are often faced in the reporting of clinical trials. These include multiplicity of data, covariate adjustment, subgroup analysis, assessing individual benefits and risk, analysis by intention to treat and alternatives, the interpretation of surprises (both good and bad), and enhancing the overall quality of clinical trial reports. 
